Literature DB >> 17611739

Acute dopamine D(1) and D(2) receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects.

Sumie Leung1, Rodney J Croft, Torsten Baldeweg, Pradeep J Nathan.   

Abstract

RATIONALE: Schizophrenia is commonly associated with an impairment in pre-attentive change detection, as represented by reduced mismatch negativity (MMN), an auditory event related potential. While the neurochemical basis of MMN has been linked to the integrity of the glutamatergic system involving N-methyl-D-aspartate (NMDA) receptors, the role of the dopaminergic system and in particular, the role of D(1) and D(2) receptors on MMN is yet to be determined.
OBJECTIVES: The aim of the present project was to investigate the acute effects of dopamine D(2) (bromocriptine) and D(1)/D(2) (pergolide) receptor stimulation on the human MMN in healthy subjects.
METHODS: Fifteen healthy male subjects participated in a double-blind, placebo-controlled, cross-over design in which each subject was tested under three acute treatment conditions separated by a 1-week wash out period; placebo, bromocriptine (2.5 mg) and pergolide (0.1 mg). The subjects were exposed to a duration-MMN paradigm with 50 ms standard tones (91%) and 100 ms deviant tones (9%).
RESULTS: The results showed that neither D(2) receptor stimulation with bromocriptine, nor simultaneous D(1) and D(2) receptor stimulation with pergolide, modulated MMN.
CONCLUSIONS: These findings suggest that acute D(1) and D(2) receptor stimulation does not modulate MMN. While the role of dopamine cannot be completely ruled out, the findings support the view that the aberrant MMN reported in schizophrenia may be linked primarily to glutamate dysfunction involving NMDA receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611739     DOI: 10.1007/s00213-007-0865-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  62 in total

1.  Duration and frequency mismatch negativity in schizophrenia.

Authors:  P T Michie; T W Budd; J Todd; D Rock; H Wichmann; J Box; A V Jablensky
Journal:  Clin Neurophysiol       Date:  2000-06       Impact factor: 3.708

2.  Towards optimal recording and analysis of the mismatch negativity.

Authors:  J Sinkkonen; M Tervaniemi
Journal:  Audiol Neurootol       Date:  2000 May-Aug       Impact factor: 1.854

3.  Stability of the mismatch negativity under different stimulus and attention conditions.

Authors:  N Kathmann; T Frodl-Bauch; U Hegerl
Journal:  Clin Neurophysiol       Date:  1999-02       Impact factor: 3.708

4.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

5.  Acute nicotine fails to alter event-related potential or behavioral performance indices of auditory distraction in cigarette smokers.

Authors:  Verner J Knott; Carole S Scherling; Crystal M Blais; Jordan Camarda; Derek J Fisher; Anne Millar; Judy F McIntosh
Journal:  Nicotine Tob Res       Date:  2006-04       Impact factor: 4.244

6.  Neural effects of nicotine during auditory selective attention in smokers: an event-related potential study.

Authors:  Verner Knott; Crystal Blais; Carole Scherling; Jordan Camarda; Anne Millar; Derek Fisher; Judy McIntosh
Journal:  Neuropsychobiology       Date:  2006-04-04       Impact factor: 2.328

7.  Dissociation of the mismatch negativity and processing negativity attentional waveforms with nitrous oxide.

Authors:  E W Pang; B Fowler
Journal:  Psychophysiology       Date:  1999-09       Impact factor: 4.016

8.  NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia.

Authors:  S Kapur; P Seeman
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

9.  Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms.

Authors:  Kuei Y Tseng; Patricio O'Donnell
Journal:  J Neurosci       Date:  2004-06-02       Impact factor: 6.167

10.  Enhanced selective attention after low-dose administration of the benzodiazepine antagonist flumazenil.

Authors:  R Smolnik; R Pietrowsky; H L Fehm; J Born
Journal:  J Clin Psychopharmacol       Date:  1998-06       Impact factor: 3.153

View more
  24 in total

Review 1.  N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Brain Res Bull       Date:  2010-04-24       Impact factor: 4.077

Review 2.  How human electrophysiology informs psychopharmacology: from bottom-up driven processing to top-down control.

Authors:  J Leon Kenemans; Seppo Kähkönen
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

3.  The effects of methylphenidate on cerebral responses to conflict anticipation and unsigned prediction error in a stop-signal task.

Authors:  Peter Manza; Sien Hu; Jaime S Ide; Olivia M Farr; Sheng Zhang; Hoi-Chung Leung; Chiang-shan R Li
Journal:  J Psychopharmacol       Date:  2016-01-11       Impact factor: 4.153

Review 4.  Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.

Authors:  Daniel C Javitt
Journal:  Ann N Y Acad Sci       Date:  2015-02-26       Impact factor: 5.691

5.  Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.

Authors:  André Schmidt; Rosilla Bachmann; Michael Kometer; Philipp A Csomor; Klaas E Stephan; Erich Seifritz; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

6.  Auditory mismatch impairments are characterized by core neural dysfunctions in schizophrenia.

Authors:  Arnim Johannes Gaebler; Klaus Mathiak; Jan Willem Koten; Andrea Anna König; Yury Koush; David Weyer; Conny Depner; Simeon Matentzoglu; James Christopher Edgar; Klaus Willmes; Mikhail Zvyagintsev
Journal:  Brain       Date:  2015-03-04       Impact factor: 13.501

7.  Neurophysiological biomarkers support bipolar-spectrum disorders within psychosis cluster.

Authors:  Manreena Kaur; Robert A Battisti; Jim Lagopoulos; Philip B Ward; Ian B Hickie; Daniel F Hermens
Journal:  J Psychiatry Neurosci       Date:  2012-09       Impact factor: 6.186

8.  Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans.

Authors:  Stephanie Thiebes; Gregor Leicht; Stjepan Curic; Saskia Steinmann; Nenad Polomac; Christina Andreou; Iris Eichler; Lars Eichler; Christian Zöllner; Jürgen Gallinat; Ileana Hanganu-Opatz; Christoph Mulert
Journal:  J Psychiatry Neurosci       Date:  2017-06       Impact factor: 6.186

9.  Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants.

Authors:  Sumie Leung; Rodney J Croft; Valérie Guille; Kirsty Scholes; Barry V O'Neill; K Luan Phan; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2009-12-10       Impact factor: 4.530

10.  Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.

Authors:  Karsten Heekeren; Jörg Daumann; Anna Neukirch; Carsten Stock; Wolfram Kawohl; Christine Norra; Till D Waberski; Euphrosyne Gouzoulis-Mayfrank
Journal:  Psychopharmacology (Berl)       Date:  2008-05-18       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.